

Sponsored Prospective Clinical Trials

2017 –	Prospective Cohort Study to Describe Practice Patterns and Outcomes in Pediatric Patients (Chronic Kidney Disease, Dialysis and Transplant) with Cystinosis
2017 –	Single Arm, Multi-Center Study to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients with Chronic Kidney Disease on Dialysis or Not Yet on Dialysis
2016 –	A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Chronic Kidney Disease and Hyperkalemia
2015 –	Practice Patterns and Outcomes of Acthar Use in Children with Nephrotic Syndrome
2015 – 2017	A Multicenter Single-Arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis
2015 – 2016	Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis
2014 – 2017	A Muticenter Registry to Evaluate the Long-Term Safety and Tolerability of Maintenance Treatment with Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 years with Chronic Kidney Disease (CKD)
2014 – 2017	A Randomized, Open-Label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
2012 – 2016	Prospective Cohort Study to Describe Practice Patterns and Safety Events in Pediatric Dialysis Patients Treated and Not Treated with Cinacalcet in the NAPRTCS Registry
2011 – 2016	An Open-Label, Single-Arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to <6 years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
2011 – 2015	A 2-Week Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
2011 – 2014	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
2010 – 2015	A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Ferumoxytal Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Nondialysis-dependent Chronic Kidney Disease
2010 – 2015	An Open-Label Study of the Safety and Efficacy of Ferumoxytal for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease



Sponsored Prospective Clinical Trials

2010 – 2012	A Prospective, Multicenter Study to Evaluate the Safety of Vitamin D Receptor Activators as Determined by Hypercalcemia in Pediatric Patients ages 0 to 16 with Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) within Current Clinical Practice
2010 – 2011	A Retrospective Observational Study to Describe Changes in Biochemical Markers and Occurrence of Safety Events Following Treatment with Cinacalcet HCl in Pediatric Subjects with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
2009 – 2012	Immunosuppression Minimization to Single Drug Therapy with Sirolimus (Rapamune®) in Pediatric Transplantation (CTOT-01)
2008 – 2014	A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbopoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects with Chronic Kidney Disease and Not Receiving Dialysis.
2006 – 2012	B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection (CTOT-02 and CCTPT-02)
2005 – 2010	Primary Vesicoureteral Reflux in Children (RIVUR)
2005 – 2010	Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric CKD Patients
2003 –	Prospective Study of Chronic Kidney Disease in Children (CKiD)
2003 – 2008	A Randomized, Multi-Center Comparative Trial of Tacrolimus with Steroids and Standard Daclizumab Induction Versus a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol with Extended Daclizumab Induction in Pediatric Renal Transplantation (SNS01)
2003 – 2008	A Phase II Exploratory Study to Determine the Safety and Study of the Immunomodulatory Functions of Induction Therapy with Campath-1H, Combined with Chronic Immunosuppression with MMF and Sirolimus (PC01 and PT01)
2003 – 2004	Darbopoetin Alfa in the Treatment of Anemia in Pediatric Patients with Chronic Kidney Disease
2003 – 2004	Open-Label, Multi-Center Study of the Safety and Efficacy of Ferrelicit® in Maintenance of Iron Stores in Pediatric Hemodialysis Patients Receiving Epoetin
2003 – 2004	Randomized Double-Blind Parallel Group Multi-Center Study of the Efficacy of Two Doses of Ferrelicit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin
2002 – 2008	Optimal Treatment of Focal Segmental Glomerulosclerosis (FSGS)
2001 – 2004	Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation (CN01)
2000 – 2003 (Pred	Safety and Efficacy of HMR4396 for the Management of Anemia in Children with Chronic Renal Failure dialysis, Hemodialysis, Peritoneal Dialysis)
1999 – 2006	A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus and Cyclosporine-Treated Primary

Transplant Recipients (SW01)



Sponsored Prospective Clinical Trials

1999 – 2002	An Open-Label, Comparative Study of the Effect of Sirolimus vs. Standard Treatment on Clinical Outcomes and Histologic Progression of Allograft Nephropathy in High-Risk Pediatric Renal Transplant Recipients
1997 – 2000	Recombinant Human Growth Hormone (Nutropin) in Pediatric Dialysis Patients
1996 – 1999	The Use of Recombinant Human Growth Hormone (Nutropin) in Children Post-Renal Transplantation
1994 – 2002	Trial of Induction Therapy in Renal Transplantation (IN01)